148 related articles for article (PubMed ID: 34054689)
1. Surrogate Cerebrospinal Fluid Biomarkers for Assessing the Efficacy of Gene Therapy in Hurler Syndrome.
Haseloff RF; Trudel S; Birke R; Schümann M; Krause E; Gomila C; Heard JM; Blasig IE; Ausseil J
Front Neurol; 2021; 12():640547. PubMed ID: 34054689
[TBL] [Abstract][Full Text] [Related]
2. Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.
Hinderer C; Bell P; Louboutin JP; Zhu Y; Yu H; Lin G; Choa R; Gurda BL; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Tarantal AF; Casal ML; Haskins ME; Wilson JM
Mol Ther; 2015 Aug; 23(8):1298-1307. PubMed ID: 26022732
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
[TBL] [Abstract][Full Text] [Related]
4. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.
Oussoren E; Keulemans J; van Diggelen OP; Oemardien LF; Timmermans RG; van der Ploeg AT; Ruijter GJ
Mol Genet Metab; 2013 Aug; 109(4):377-81. PubMed ID: 23786846
[TBL] [Abstract][Full Text] [Related]
5. Mucopolysaccharidosis type I.
Wraith JE; Jones S
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
[TBL] [Abstract][Full Text] [Related]
6. Diagnosing lysosomal storage disorders: mucopolysaccharidosis type I.
Johnson BA; Dajnoki A; Bodamer OA
Curr Protoc Hum Genet; 2015 Jan; 84():17.17.1-17.17.8. PubMed ID: 25599668
[TBL] [Abstract][Full Text] [Related]
7. Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.
Hinderer C; Bell P; Louboutin JP; Katz N; Zhu Y; Lin G; Choa R; Bagel J; O'Donnell P; Fitzgerald CA; Langan T; Wang P; Casal ML; Haskins ME; Wilson JM
Mol Genet Metab; 2016 Sep; 119(1-2):124-30. PubMed ID: 27386755
[TBL] [Abstract][Full Text] [Related]
8. Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-H.
Raymond GV; Pasquali M; Polgreen LE; Dickson PI; Miller WP; Orchard PJ; Lund TC
Sci Rep; 2016 Dec; 6():38305. PubMed ID: 27910891
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of the molecular lesion causing mucopolysaccharidosis type I in cats.
He X; Li CM; Simonaro CM; Wan Q; Haskins ME; Desnick RJ; Schuchman EH
Mol Genet Metab; 1999 Jun; 67(2):106-12. PubMed ID: 10356309
[TBL] [Abstract][Full Text] [Related]
10. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy.
Traas AM; Wang P; Ma X; Tittiger M; Schaller L; O'donnell P; Sleeper MM; Vite C; Herati R; Aguirre GD; Haskins M; Ponder KP
Mol Ther; 2007 Aug; 15(8):1423-31. PubMed ID: 17519893
[TBL] [Abstract][Full Text] [Related]
11. Safe and Sustained Expression of Human Iduronidase After Intrathecal Administration of Adeno-Associated Virus Serotype 9 in Infant Rhesus Monkeys.
Hordeaux J; Hinderer C; Buza EL; Louboutin JP; Jahan T; Bell P; Chichester JA; Tarantal AF; Wilson JM
Hum Gene Ther; 2019 Aug; 30(8):957-966. PubMed ID: 31017018
[TBL] [Abstract][Full Text] [Related]
12. Recombinant alpha-L-iduronidase: characterization of the purified enzyme and correction of mucopolysaccharidosis type I fibroblasts.
Unger EG; Durrant J; Anson DS; Hopwood JJ
Biochem J; 1994 Nov; 304 ( Pt 1)(Pt 1):43-9. PubMed ID: 7998955
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
[TBL] [Abstract][Full Text] [Related]
14. Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice.
Hinderer C; Katz N; Louboutin JP; Bell P; Yu H; Nayal M; Kozarsky K; O'Brien WT; Goode T; Wilson JM
Hum Gene Ther; 2016 Nov; 27(11):906-915. PubMed ID: 27510804
[TBL] [Abstract][Full Text] [Related]
15. Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan.
Chuang CK; Lin HY; Wang TJ; Huang YH; Chan MJ; Liao HC; Lo YT; Wang LY; Tu RY; Fang YY; Chen TL; Ho HC; Chiang CC; Lin SP
Orphanet J Rare Dis; 2018 May; 13(1):84. PubMed ID: 29801497
[TBL] [Abstract][Full Text] [Related]
16. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I.
Belur LR; Romero M; Lee J; Podetz-Pedersen KM; Nan Z; Riedl MS; Vulchanova L; Kitto KF; Fairbanks CA; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
Front Mol Neurosci; 2021; 14():618360. PubMed ID: 34040503
[TBL] [Abstract][Full Text] [Related]
18. Cognitive Abilities of Dogs with Mucopolysaccharidosis I: Learning and Memory.
Provoost L; Siracusa C; Stefanovski D; Che Y; Li M; Casal M
Animals (Basel); 2020 Feb; 10(3):. PubMed ID: 32121123
[TBL] [Abstract][Full Text] [Related]
19. Four novel mutations underlying mild or intermediate forms of alpha-L-iduronidase deficiency (MPS IS and MPS IH/S).
Tieu PT; Bach G; Matynia A; Hwang M; Neufeld EF
Hum Mutat; 1995; 6(1):55-9. PubMed ID: 7550232
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
